MYL Mylan N.V.

21.65
-0.01  -0%
Previous Close 21.66
Open 21.67
Price To Book 0.98
Market Cap 11,174,269,058
Shares 516,132,520
Volume 5,655,328
Short Ratio
Av. Daily Volume 7,111,710
Stock charts supplied by TradingView

NewsSee all news

  1. Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules, USP, Due to the Detection of Trace Amounts of NDMA (N-Nitrosodimethylamine) Impurity Found in the Active Pharmaceutical Ingredient Manufactured by Solara Active Pharma Sciences Limited

    HERTFORDSHIRE, England, and PITTSBURGH, Jan. 8, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ:MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall, to the consumer

  2. Mylan to Present at the 38th Annual J.P. Morgan Healthcare Conference

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 6, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ:MYL) today announced that Chairman Robert J. Coury, together with Upjohn's Group President Michael

  3. Pfizer and Mylan Announce Two Future Viatris Board Members

    Ian Read and James Kilts offer strong experience to support long-term value creation Pfizer Inc. (NYSE:PFE) and Mylan N.V. (NASDAQ:MYL) today announced that Ian Read and James Kilts will join the Viatris board of

  4. Pfizer and Mylan Announce Two Future Viatris Board Members

    NEW YORK, Dec. 18, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE:PFE) and Mylan N.V. (NASDAQ:MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination

  5. Annual Changes to the NASDAQ-100 Index

    NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual evaluation of the NASDAQ-100 Index® (NASDAQ:NDX), which will become effective prior to market open on Monday,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced October 4, 2017.
Glatiramer Acetate Injection - Generic for Copaxone
Multiple sclerosis (MS)
Approval announced June 4, 2018.
MYL-1401H
Neulasta biosimilar
PDUFA date originally set for September 3 extended by three months to December 3, 2017. Advisory Committee Meeting July 13, 2017 voted 16-0 recommending approval. Approval announced December 1, 2017.
Ogivri - trastuzumab biosimilar
Trastuzumab biosimilar
FDA Approval announced November 9, 2018.
Revefenacin
COPD

Latest News

  1. Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules, USP, Due to the Detection of Trace Amounts of NDMA (N-Nitrosodimethylamine) Impurity Found in the Active Pharmaceutical Ingredient Manufactured by Solara Active Pharma Sciences Limited

    HERTFORDSHIRE, England, and PITTSBURGH, Jan. 8, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ:MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall, to the consumer

  2. Mylan to Present at the 38th Annual J.P. Morgan Healthcare Conference

    HERTFORDSHIRE, England and PITTSBURGH, Jan. 6, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ:MYL) today announced that Chairman Robert J. Coury, together with Upjohn's Group President Michael

  3. Pfizer and Mylan Announce Two Future Viatris Board Members

    Ian Read and James Kilts offer strong experience to support long-term value creation Pfizer Inc. (NYSE:PFE) and Mylan N.V. (NASDAQ:MYL) today announced that Ian Read and James Kilts will join the Viatris board of

  4. Pfizer and Mylan Announce Two Future Viatris Board Members

    NEW YORK, Dec. 18, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE:PFE) and Mylan N.V. (NASDAQ:MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination

  5. Annual Changes to the NASDAQ-100 Index

    NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual evaluation of the NASDAQ-100 Index® (NASDAQ:NDX), which will become effective prior to market open on Monday,

  6. Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.

      HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Dec. 2, 2019 /PRNewswire/ -- Mylan N.V.  (NASDAQ:MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the U.S. launch

  7. Mylan to Present at the Evercore ISI HealthCONx Conference

    HERTFORDSHIRE, England and PITTSBURGH, Nov. 25, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ:MYL) today announced that it will present at the Evercore ISI HealthCONx Conference in Boston on

  8. Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

    Mylan N.V. (NASDAQ:MYL) and Pfizer Inc. (NYSE:PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced

  9. Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

    HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ:MYL) and Pfizer Inc. (NYSE:PFE) today announced that the name of the new company to be formed by the planned combination

  10. EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Mylan N.V.

    NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Mylan N.V. ("Mylan" or "the Company") (NASDAQ:MYL) concerning possible violations of federal

  11. Mylan Reports Third Quarter 2019 Results and Updates 2019 Guidance

    HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ:MYL) today announced its financial results for the three and nine months ended September 30, 2019. Third Quarter 2019 Financial

  12. Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance

    MORGANTOWN, W.Va., Oct. 25, 2019 /PRNewswire/ -- Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level.

  13. Mylan Finalizes Previously Disclosed Settlement with U.S. Securities and Exchange Commission

    HERTFORDSHIRE, England, and PITTSBURGH, Sept. 27, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ:MYL) today announced that it has finalized a previously disclosed civil settlement with the U.S. Securities and Exchange

  14. Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer

    HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ:MYL) today announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic

  15. Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019

    Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019 to be held in Helsinki, Sweden on